The enormous diversity of HIV-1 presents a formidable challenge for developing an effective AIDS vaccine. In this issue of Cell, Barouch et al. show that bioinformatically designed antigens, pieced together from multiple HIV immune epitopes, partially protect rhesus macaques from simianhuman immunodeficiency virus infection. This ''mosaic'' approach holds promise for the development of broadly protective vaccines.
Development of an effective AIDS vaccine has proven a daunting task and yielded disappointing results for many years. Recently, however, some exciting progress has been made. The RV144 (or Thai) trial provided the first evidence that vaccination may lower the risk of acquiring HIV-1 infection (Rerks-Ngarm et al., 2009) . Although the protective effects were marginal, this finding revitalized the field. Furthermore, novel powerful techniques have allowed the characterization of a substantial number of highly potent broadly neutralizing antibodies (Klein et al., 2013) . Nonetheless, the induction of immune responses that are effective against the highly diverse HIV-1 strains circulating worldwide still represents a major challenge. The report by Barouch et al. (2013) in this issue of Cell takes a step toward overcoming the obstacle of strain diversity, showing that an HIV-1 mosaic vaccine partially protects rhesus macaques against the acquisition and pathogenic effects of a simianhuman immunodeficiency virus, termed SHIV-SF162P3.
Any vaccine approach aiming for global protection against HIV/AIDS must find some way to counter viral sequence diversity. Potential strategies under exploration include the development of regional, clade-specific HIV-1 vaccines and the induction of immune responses against highly conserved viral epitopes. However, the first approach is complicated because it requires the development, application, and approval of multiple effective vaccines, and the latter has thus far failed to induce broadly protective responses.
Another strategy being developed is the use of sequence information from globally circulating virus strains to design a composite HIV-1 vaccine based on a limited number of so called ''mosaic'' sequences. Mosaic antigens are generated by bioinformatically integrating regions of natural HIV-1 sequence that contain a maximum of potential T cell epitopes (Fischer et al., 2007) . The resulting polyvalent synthetic vaccines cover the sequence diversity of thousands of peptides, thereby enabling the delivery of a diverse range of epitopes with a single vaccine shot. As anticipated, mosaic antigens induce broader cellular and humoral immune responses than conventional wild-type or consensus HIV-1 antigens (Barouch et al., 2010; Santra et al., 2010) . However, whether or not mosaic vaccines exert any protective effects in vivo remained to be determined.
To address this question, the authors used bivalent (i.e., two variants of) mosaic antigens containing HIV-1 gag, pol, and env sequences inserted into replicationdefective adeno (AD) or modified vaccinia Ankara (MVA) vectors for immunization by a prime-boost approach (outlined in Figure 1 ). Six rounds of rectal challenge with a heterologous, difficult-to-neutralize hybrid simian-human immunodeficiency virus, SHIV-SF162P3, simulated sexual exposure. Immunization with the mosaic vaccine did not confer complete protection or ''sterilizing'' immunity but reduced the risk of SHIV infection per intrarectal challenge by about 90%. This effect is impressive as the infectious viral dose was substantially higher than those typically encountered during sexual exposure to HIV-1 in humans. Importantly, 5 of 12 control animals, but none of the vaccinated macaques, had died from simian AIDS by 9 months postchallenge. Thus, treatment with mosaic HIV-1 antigens protected the animals against both the acquisition of SHIV infection and development of fatal disease.
These protective effects are particularly remarkable because the challenge virus encodes the Gag and Pol proteins of SIVmac239, which do not cross-react with the HIV-1 mosaic Gag and Pol immunogens in the vaccine. On the one hand, this limits the significance of the study because it does not allow evaluation of the contribution of Gag-and Pol-directed cellular immune responses to virological control. On the other hand, this makes the results even more intriguing because they suggest that Env-specific immune responses alone confer significant protection against the pathogenic outcome of infection.
Peak and set-point viral loads were only modestly reduced in the vaccinated animals. However, Gag-specific cellular immune responses would most likely greatly increase virological control of wild-type HIV-1 strains. In fact, HIV-1 mosaic antigens were shown previously to induce particularly broad and effective cellular immune responses (Barouch et al., 2010; Santra et al., 2010) , and similar primeboost vaccine regimens using SIV antigens reduced the set point viral loads by more than two orders of magnitude (Barouch et al., 2012) . Currently, it is not possible to determine the effects of HIV-1 Gag-and Pol-specific immune responses in nonhuman primate models. However, expanded understanding of the determinants of host specificity may allow the generation of simiantropic HIV-1 strains containing minimal portions of SIV sequences for direct efficacy testing of HIV-1 Gag-Pol CTL responses in macaques (Hatziioannou and Evans, 2012) .
Notably, Barouch and colleagues identified several correlates of protection, including low levels of neutralizing antibodies in sera from vaccinated macaques, antibody-dependent complement deposition, and antibodydependent cellular phagocytosis, indicating a contribution of both neutralizing and nonneutralizing antibody responses to the protective effects. Env-specific antibodies were also identified as a correlate of protection in the RV144 clinical vaccine trial (Haynes et al., 2012) . In contrast to the human trial, however, Barouch and coworkers did not find evidence for a protective role of antibodies directed against the V2 loop in HIV-1 Env. Altogether, the mechanisms underlying the protective effects in the present study seem to be complex and remain to be fully defined.
Although the results presented in Barouch et al. (2013) are exciting, they come with an important caveat. The main goal of mosaic HIV-1 vaccines is to induce broad immune responses that are effective against the highly diverse HIV-1 strains circulating worldwide. Yet, only a single SHIV strain was utilized in the present study, and it therefore does not clarify whether mosaic antigens confer protection against different HIV-1 strains. It is encouraging, however, that the SHIV-SF162P3 challenge virus seems to be highly stringent. SHIVs utilized in previous studies typically expressed easy-to-neutralize tier 1 Env proteins were frequently spontaneously controlled and usually did not induce disease. In contrast, the SHIV-SF162P3 virus utilized in the present study shows a difficult-to-neutralize tier 2 phenotype, maintains high set point viral loads in most control animals (>5 logs of viral RNA copies/ml), and, perhaps most importantly, was associated with rapid progression to simian AIDS in 5 of 12 control animals. The finding that the mosaic vaccine induced significant protection against an apparently highly stringent challenge virus suggests that it may also be effective against highly pathogenic HIV-1 strains in human trials, although it will be important to further examine the breadth of the protective effects in future studies once suitable additional stringent challenge strains have been identified. Many important questions remain. What kind of efficacy can be expected for mosaic HIV vaccines in humans in whom the viral doses encountered during sexual exposures to HIV-1 are usually substantially lower than those used in the present study? Will semen that is present during most sexual transmissions of HIV-1 and increases its infectiousness (Mü nch et al., 2007) affect the protective effects? As no complete protection was achieved by immunization, it will also be important to clarify whether viral escape variants that cause disease may emerge in the long term. These and other questions on the efficacy of mosaic HIV-1 vaccines can only be addressed in humans, and testing of this concept in clinical trials seems highly warranted. In silico optimization of mosaic HIV-1 M Gag/Pol/Env immunogens was performed to maximize coverage of potential T cell epitopes. Healthy rhesus macaques (green) were primed using adenoviral vector regimens expressing bivalent mosaic immunogens. At week 12, animals were boosted with either Adenoviral (Ad) or modified vaccine Ankara (MVA) vector regimens. Starting 52 weeks postimmunization, repetitive intrarectal challenges with chimeric SHIV-SF162P3 were performed to evaluate vaccine-mediated protection. Infection of immunized animals (indicated in orange) was delayed, and no AIDS-related mortality was observed, whereas 5 out of 12 nonimmunized animals died (red).
From tiny viruses to complex vertebrates, biological systems share a common challenge to preserve reproductive fitness in unpredictable, changing environments. Faced with environmental variability, many organisms evolve complex sensoractuators to continually gauge their surroundings and deterministically adapt. But, 50 years ago, Dan Cohen proposed an alternate solution: if organisms could stochastically generate a range of phenotypes in each environment, they could ''hedge their bets'' in much the same way that financial houses diversify their assets to minimize risk against economic crashes. In desert annuals, where reproductive success is governed by unpredictable weather patterns, Cohen noted that fitness could be enhanced if chance governed each seed's fate to germinate or hibernate (e.g., when the husk thickness of each seed is allowed to stochastically vary). With some seeds randomly entering dormancy whatever the environment, the annuals are always left with a long-lived subpopulation to avoid extinction during unforeseen droughts. But what molecular mechanism would allow organisms to probabilistically generate the needed cell-to-cell variability? Years later, studies of active-versus-dormant infection (i.e., lysis-lysogeny) in the bacterial virus phage l suggested an answer: noisy gene expression (Arkin et al., 1998) . Gene expression is, in fact, inherently stochastic, subject to random fluctuations in regulating enzymes, mRNAs, and other biomolecules. These diffusiondriven molecular fluctuations are unavoidable at the single-cell level and appear sufficient to shift cells between transcriptional on and off states (Raj and van Oudenaarden, 2008) . With some cells randomly active and others dormant, the result is a distribution of cell fates across a population. A similar distribution of cell fates may now have been found in HIV patients in the clinic. In this issue of Cell, Ho and colleagues (Ho et al., 2013) report that HIV's reactivation from lifelong dormant (i.e., ''latent'') reservoirs is stochastic, likely interfering with persistent therapeutic efforts to activate and purge this problematic reservoir.
The theory that stochastic noise is sufficient to drive cell-fate decisions has been demonstrated in a range of biological systems, from bacteria to vertebrates (Balá zsi et al., 2011) . Nevertheless, the theory has faced stiff challenge. Alternative hypotheses have argued that hidden deterministic variables, for example the state of the host cell during viral infection or the number of infecting viruses, have a larger impact on eventual cell-fate (St-Pierre and Endy, 2008; Zeng et al., 2010) . Unknown and unmeasured, these variables might strongly differ between the disparate cellular phenotypes, in fact predicting the seeming stochasticity. Ever finer and more expansive measurements, it appeared, would be needed to rule out deterministic explanations.
Unexpectedly, a new chapter may now come from a clinical angle. Much like bacteriophage l, when HIV infects a cell, two outcomes are possible. After HIV integrates its proviral DNA into the genome of CD4 + T cells, either it enters a state of active replication killing the cell or it enters a long-lived latent state where
